Renal Transplantation
Conditions
Brief summary
This multicentre, prospective, randomized, open-label study will compare the safety and efficacy of mycophenolate mofetil with delayed introduction of sirolimus and discontinuation of cyclosporine, with those of mycophenolate mofetil and long term continuation of cyclosporine in renal transplant recipients receiving daclizumab (Zenapax) as induction treatment and followed by 8 month treatment with corticosteroids. The anticipated time on study treatment is 12 months. Participants who will complete the initial 12-month study and who will provide written informed consent will be eligible to participate in a 60-month follow-up phase.
Interventions
DRUGCyclosporine
Cyclosporine tablets orally once daily at dose level adapted to maintain concentration at 2 hours after administration (C2): 1000-1500 nanogram per milliliter (ng/mL) during Day 0 to Week 4, and 800-1200 ng/mL during Week 4 to Week 52. For Mycophenoate Mofetil + Sirolimus treatment arm, at Week 12, dose of cyclosporine will be reduced by 50% for 3 days, followed by 1/4 of the dose for 3 days, and then cyclosporine will be stopped.
DRUGDaclizumab
Daclizumab 2 milligram (mg) per kilogram (kg) will be administered as intravenous infusion over 15 minute on Day 0 (during the 24 hours preceding renal transplantation) and at a dose of 1 mg/kg on Day14.
Mycophenoate mofetil 1 gram (g) (2\*500mg tablets or 4\*250mg capsules) will be given twice daily (daily dose of 2 g) orally for 12 months.
DRUGPrednisolone
Prednisolone 250 mg intravenously on Day 0, followed by 0.5 mg/kg orally daily (maximum 40 mg daily) from Day 1 to Day 7, then 0.25 mg/kg orally daily (maximum 20 mg daily), then dose will be stepwise reduced by 2.5 mg per week to reach to a dose level of 10 mg daily and continued up to 6 months and finally drug will be discontinued after 8 months.
DRUGSirolimus
Sirolimus tablets will be given orally from week 12 to week 52, starting with loading dose of 10 mg daily for 2 days followed by 6 mg daily to adapt to trough concentrations of 8-15 ng/mL from week 12 to week 39, and 5-10 ng/mL from week 39 to week 52.
Sponsors
Hoffmann-La Roche
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Receipt of a first cadaveric kidney graft * Antilymphocyte antibodies and panel reactive antibodies (PRA) less than 30 percent (%) (historical peak and/or current value) * Cold ischaemia time less than or equal to 36 hours
Exclusion criteria
* Kidney from a living donor; donor greater than (\>) 65 years of age; second renal graft, or more; or multiple organ transplant * Known hypersensitivity to any of the drugs in the study or their components * History of cancer or malignancy during previous 5 years, other than successfully treated spinocellular or basal cell cancer * Participant presenting, on inclusion, either symptoms suggestive of active gastroduodenal ulcer, or gastroduodenal ulcer confirmed by fibroscopy and biopsy, and requiring treatment * Participant with severe refractory hyperlipidaemia * Pregnant woman or nursing mother
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Creatinine Clearance Calculated and Corrected According to Cockcroft Gault at Month 60 | 60 months |
| Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | Up to approximately 12 months |
| Number of Participants With Serious Adverse Events (SAEs) | From 12 months up to 60 months |
| Creatinine Clearance Calculated and Corrected According to Cockcroft Gault at Week 52 | 52 weeks |
| Number of Participants With Cancers and Lymphoproliferative Syndromes | Up to approximately 12 months |
| Number of Participants With Premature Discontinuations due to Adverse Events (AEs) | Up to approximately 12 months |
| Change From Baseline in 24-Hour Urinary Protein at Week 52 | 52 weeks |
Secondary
| Measure | Time frame |
|---|---|
| Number of Participants With Histologic Evaluation of the Graft | Week 52 |
| Mean Inverse Creatinine Concentration | Week 4, 8, 12, 14, 16, 26, 39, and 52 |
| Number of Participants With Graft Survival | Month 60 |
| Number of Participants Who Were Alive | Month 60 |
| Creatinine Clearance Calculated and Corrected According to Cockcroft-Gault | Week 4, 8, 12, 14, 16, 26, 39, and 52 |
| Glomerular Filtration Rate (GFR) Measured by Iohexol Clearance | Baseline, Week 52 |
| Number of Participants with Response to Treatment, Defined as Creatinine Clearance >/=60 mL/min at Week 52 | Week 52 |
| Number of Participants With Treated Rejections | Baseline up to Week 52 |
| Mean Serum Creatinine Concentration | Week 4, 8, 12, 14, 16, 26, 39, and 52 |
| Number of Participants With Biopsy-proven Acute Rejections | Baseline up to Month 60 |
Countries
France
Outcome results
None listed